CD19 and mantle cell lymphoma: In contrast, brexucabtagene autoleucel, another CD19-directed CAR-T therapy that received accelerated FDA approval in July 2020 for the treatment of relapsed or refractory mantle cell lymphoma, did not have an analogous phase 3 RCT registered at ClinicalΤrials.gov as of our data cutoff.